
Maximum Fair Prices are reshaping Part D formularies, with plans favoring lower net-cost options, panelists said at AMCP Nexus 2026.

Lisa Cashman, PharmD, is vice president of payer strategy at Lumanity.

Maximum Fair Prices are reshaping Part D formularies, with plans favoring lower net-cost options, panelists said at AMCP Nexus 2026.